Tyrosine kinase inhibitors: Multi-targeted or single-targeted?

doi:10.5306/wjco.v2.i2.80

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 2, Issue 2

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9643)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-5) series.

Item

Count

PDF

749

HTML

8060

Figures (1-1)

464

Tables (1-5)

370

Sum=9643

Feb 10, 2011 (publication date) through Nov 8, 2024

Times Cited of This Article

Times Cited (171)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Clin Oncol. Feb 10, 2011; 2(2): 80-93
Published online Feb 10, 2011. doi: 10.5306/wjco.v2.i2.80

Table 3 Tyrosine kinase inhibitors of the platelet derived growth factor receptor tyrosine kinase family

Inhibitor	Tyrosine kinase target	Neoplasm(s) targeted	Clinical status
Leflunomide (SU101)	PDGFRβ, EGFR, FGFR	Prostate cancer	Phase II/III
Lestaurtinib (CEP-701)	Flt3, Trk, VEGFR2	Leukemia, pancreatic, AML	Phase II
Tandutinib (MLN518)	Flt3, PDGFRβ, Kit	AML	Phase I/II
SU14813	VEGFR2, PDGFRβ, Flt3	Adv malignancies	Phase I, suspended
XL999	FGFR, VEGFR1/2/3, PDGFRβ, Flt3	Cancer	Phase II, suspended
VX-322	Flt3, Kit	AML	Preclinical
SU5614	Flt3	AML, solid tumors	Preclinical, suspended
GTP-14564	Flt3	AML	Preclinical
KI23819	Flt3	AML	Preclinical
Gö6976	Flt3, JAK2	AML	Preclinical
AG1296	PDGFRβ, Kit, Flt3	AML	Preclinical
PKC412	Kit, PDGFRβ, PKC, Flt3, VEGFR2	Solid tumors	Phase II
OSI 817	Kit, VEGFR	Solid tumors	Preclinical
CP-868596	PDGFRβ	Adv solid tumors	Phase I
CP-868596	PDGFRβ	NSCLC	Phase II

Trk: Nerve growth factor receptor tyrosine kinase; PKC: Protein kinase C; RCC: Renal cell carcinoma; HN: Head and neck cancer; NSCLC: Non small cell lung cancer; PDGFR: Platelet derived growth factor receptor; EGFR: Epidermal growth factor receptor; AML: Acute myeloid leukaemia.

Citation: Broekman F, Giovannetti E, Peters GJ. Tyrosine kinase inhibitors: Multi-targeted or single-targeted? World J Clin Oncol 2011; 2(2): 80-93
URL: https://www.wjgnet.com/2218-4333/full/v2/i2/80.htm
DOI: https://dx.doi.org/10.5306/wjco.v2.i2.80